;PMID: 2098522
;source_file_911.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..33] = [t:0..33]
;1)sentence:[e:39..91] = [t:39..91]
;2)section:[e:95..167] = [t:95..166]
;3)section:[e:171..259] = [t:171..259]
;4)sentence:[e:263..430] = [t:263..430]
;5)sentence:[e:431..687] = [t:431..687]
;6)sentence:[e:688..890] = [t:688..890]
;7)sentence:[e:892..1080] = [t:892..1080]
;8)sentence:[e:1081..1246] = [t:1081..1246]
;9)section:[e:1250..1294] = [t:1250..1293]
;Sentence Matching Errors
;ERROR_Section end mismatch[e:95..167][t:95..166]
;ERROR_Section end mismatch[e:1250..1294][t:1250..1293]
;Token/POS Errors
;ERROR_Token in entity file but not tree[166..167] .
;ERROR_Token in entity file but not tree[1293..1294] ]

;section 0 Span:0..33
;J Enzyme Inhib. 1990;4(2):159-67.
(SEC
  (FRAG (NNP:[0..1] J) (NNP:[2..8] Enzyme) (NNP:[9..14] Inhib) (.:[14..15] .)
        (CD:[16..20] 1990) (::[20..21] ;) (CD:[21..22] 4) (-LRB-:[22..23] -LRB-)
        (CD:[23..24] 2) (-RRB-:[24..25] -RRB-) (::[25..26] :) (CD:[26..29] 159)
        (::[29..30] -) (CD:[30..32] 67) (.:[32..33] .)))

;sentence 1 Span:39..91
;Endocrine and antitumoral effects of R76713 in rats.
;[76..82]:substance:"R76713"
(SENT
  (NP-HLN
    (NP
      (NP (NN:[39..48] Endocrine)
        (NML-1 (-NONE-:[48..48] *P*)))
      (CC:[49..52] and)
      (NP (JJ:[53..64] antitumoral)
        (NML-1 (NNS:[65..72] effects))))
    (PP (IN:[73..75] of)
      (NP (NN:[76..82] R76713)))
    (PP-LOC (IN:[83..85] in)
      (NP (NNS:[86..90] rats)))
    (.:[90..91] .)))

;section 2 Span:95..166
;De Coster R, Van Ginckel R, Wouters W, Goeminne N, Vanherck W, Byloos M
(SEC
  (FRAG (NNP:[95..97] De) (NNP:[98..104] Coster) (NNP:[105..106] R)
        (,:[106..107] ,) (NNP:[108..111] Van) (NNP:[112..119] Ginckel)
        (NNP:[120..121] R) (,:[121..122] ,) (NNP:[123..130] Wouters)
        (NNP:[131..132] W) (,:[132..133] ,) (NNP:[134..142] Goeminne)
        (NNP:[143..144] N) (,:[144..145] ,) (NNP:[146..154] Vanherck)
        (NNP:[155..156] W) (,:[156..157] ,) (NNP:[158..164] Byloos)
        (NNP:[165..166] M)))

(ORPH .)

;section 3 Span:171..259
;Department of Endocrinology and Oncology, Janssen Research Foundation,
;Beerse,  Belgium.
(SEC
  (FRAG (NNP:[171..181] Department) (IN:[182..184] of)
        (NNP:[185..198] Endocrinology) (CC:[199..202] and)
        (NNP:[203..211] Oncology) (,:[211..212] ,) (NNP:[213..220] Janssen)
        (NNP:[221..229] Research) (NNP:[230..240] Foundation) (,:[240..241] ,)
        (NNP:[242..248] Beerse) (,:[248..249] ,) (NNP:[251..258] Belgium)
        (.:[258..259] .)))
;ERROR_Orphan Text from Tree File[166..171] .

;sentence 4 Span:263..430
;Some effects of daily oral administration of a new non-steroidal aromatase 
;inhibitor on the pituitary-gonadal and adrenal functions were investigated in
; female rats.
;[328..337]:cyp450:"aromatase"
;[339..348]:substance:"inhibitor"
(SENT
  (S
    (NP-SBJ-2
      (NP (DT:[263..267] Some) (NNS:[268..275] effects))
      (PP (IN:[276..278] of)
        (NP
          (NP (JJ:[279..284] daily) (JJ:[285..289] oral)
              (NN:[290..304] administration))
          (PP (IN:[305..307] of)
            (NP (DT:[308..309] a) (JJ:[310..313] new)
              (ADJP (AFX:[314..317] non) (HYPH:[317..318] -)
                    (JJ:[318..327] steroidal))
              (NN:[328..337] aromatase) (NN:[339..348] inhibitor)))))
      (PP (IN:[349..351] on)
        (NP (DT:[352..355] the)
          (NML
            (NML
              (ADJP (JJ:[356..365] pituitary) (HYPH:[365..366] -)
                    (JJ:[366..373] gonadal))
              (NML-1 (-NONE-:[373..373] *P*)))
            (CC:[374..377] and)
            (NML (JJ:[378..385] adrenal)
              (NML-1 (NNS:[386..395] functions)))))))
    (VP (VBD:[396..400] were)
      (VP (VBN:[401..413] investigated)
        (NP-2 (-NONE-:[413..413] *))
        (PP-LOC (IN:[414..416] in)
          (NP (JJ:[418..424] female) (NNS:[425..429] rats)))))
    (.:[429..430] .)))

;sentence 5 Span:431..687
;At doses of 1 mg/kg twice daily or higher, R 76713 lowered plasma  estradiol
;levels to the range measured after ovariectomy Plasma progesterone  levels
;and uterine weights decreased whilst LH levels increased but to a lesser 
;extent than after ovariectomy.
;[443..444]:quantitative-value:"1"
;[445..450]:quantitative-units:"mg/kg"
;[474..481]:substance:"R 76713"
;[498..507]:substance:"estradiol"
;[562..574]:substance:"progesterone"
;[620..622]:substance:"LH"
(SENT
  (S
    (PP (IN:[431..433] At)
      (NP
        (NP (NNS:[434..439] doses))
        (PP (IN:[440..442] of)
          (UCP
            (NP
              (NP (CD:[443..444] 1) (NN:[445..447] mg))
              (PP (SYM:[447..448] /)
                (NP (NN:[448..450] kg)))
              (ADVP-TMP (RB:[451..456] twice) (JJ:[457..462] daily)))
            (CC:[463..465] or)
            (ADJP (JJR:[466..472] higher))))))
    (,:[472..473] ,)
    (NP-SBJ (NN:[474..475] R) (CD:[476..481] 76713))
    (VP (VBD:[482..489] lowered)
      (NP (NN:[490..496] plasma) (NN:[498..507] estradiol)
          (NNS:[508..514] levels))
      (PP (TO:[515..517] to)
        (VP
          (NP (DT:[518..521] the) (NN:[522..527] range))
          (VP (VBN:[528..536] measured)
            (NP (-NONE-:[536..536] *))
            (PP-TMP (IN:[537..542] after)
              (NP (NN:[543..554] ovariectomy))))))))
  (S
    (NP-SBJ
      (NP (NN:[555..561] Plasma) (NN:[562..574] progesterone)
          (NNS:[576..582] levels))
      (CC:[583..586] and)
      (NP (JJ:[587..594] uterine) (NNS:[595..602] weights)))
    (VP (VBD:[603..612] decreased)
      (SBAR-ADV (IN:[613..619] whilst)
        (S
          (NP-SBJ (NN:[620..622] LH) (NNS:[623..629] levels))
          (VP (VBD:[630..639] increased)
            (NAC (CC:[640..643] but)
              (PP (TO:[644..646] to)
                (NP
                  (NP (DT:[647..648] a) (JJR:[649..655] lesser)
                      (NN:[657..663] extent))
                  (PP (IN:[664..668] than)
                    (PP-TMP (IN:[669..674] after)
                      (NP (NN:[675..686] ovariectomy)))))))))))
    (.:[686..687] .)))
;ERROR_Sentence has multiple Children (Sentence Error)[431..687]::S:S:

;sentence 6 Span:688..890
;The other hormonal data show that long-term  administration of R 76 713 does
;not modify the gluco- and mineralocorticoid  hormone levels even at the
;highest dose studied (20 mg/kg, 4 h after treatment).
;[751..759]:substance:"R 76 713"
;[780..786]...[799..817]:substance:"gluco-"..."corticoid  hormone"
;[791..817]:substance:"mineralocorticoid  hormone"
;[859..861]:quantitative-value:"20"
;[862..867]:quantitative-units:"mg/kg"
;[869..870]:quantitative-value:"4"
;[871..872]:quantitative-units:"h"
(SENT
  (S
    (NP-SBJ (DT:[688..691] The) (JJ:[692..697] other) (JJ:[698..706] hormonal)
            (NNS:[707..711] data))
    (VP (VBP:[712..716] show)
      (SBAR (IN:[717..721] that)
        (S
          (NP-SBJ
            (NP (JJ:[722..731] long-term) (NN:[733..747] administration))
            (PP (IN:[748..750] of)
              (NP (NN:[751..752] R) (CD:[753..755] 76) (CD:[756..759] 713))))
          (VP (VBZ:[760..764] does) (RB:[765..768] not)
            (VP (VB:[769..775] modify)
              (NP (DT:[776..779] the)
                (NML
                  (NML
                    (NML (AFX:[780..785] gluco) (HYPH:[785..786] -)
                      (NML-1 (-NONE-:[786..786] *P*)))
                    (NML-2 (-NONE-:[786..786] *P*)))
                  (CC:[787..790] and)
                  (NML
                    (NML (AFX:[791..799] mineralo)
                      (NML-1 (JJ:[799..808] corticoid)))
                    (NML-2 (NN:[810..817] hormone) (NNS:[818..824] levels)))))
              (PP
                (ADVP (RB:[825..829] even))
                (IN:[830..832] at)
                (NP
                  (NP (DT:[833..836] the) (JJS:[837..844] highest)
                      (NN:[845..849] dose))
                  (VP (VBN:[850..857] studied)
                    (NP (-NONE-:[857..857] *)))
                  (PRN (-LRB-:[858..859] -LRB-)
                    (FRAG
                      (NP
                        (NP (CD:[859..861] 20) (NN:[862..864] mg))
                        (PP (SYM:[864..865] /)
                          (NP (NN:[865..867] kg))))
                      (,:[867..868] ,)
                      (PP-TMP
                        (NP-ADV (CD:[869..870] 4) (NN:[871..872] h))
                        (IN:[873..878] after)
                        (NP (NN:[879..888] treatment))))
                    (-RRB-:[888..889] -RRB-)))))))))
    (.:[889..890] .)))

;sentence 7 Span:892..1080
;Furthermore, both ovariectomy and R 76 713 treatment (1 and 5 mg/kg twice a
;day)  induced almost complete regression of
;9,12-dimethyl-1,2-benzanthracene-induced  mammary carcinoma in rats.
;[926..934]:substance:"R 76 713"
;[946..947]:quantitative-value:"1"
;[952..953]:quantitative-value:"5"
;[954..959]:quantitative-units:"mg/kg"
;[1012..1044]:substance:"9,12-dimethyl-1,2-benzanthracene"
(SENT
  (S
    (ADVP (RB:[892..903] Furthermore))
    (,:[903..904] ,)
    (NP-SBJ (CC:[905..909] both)
      (NP (NN:[910..921] ovariectomy)
        (NML-2 (-NONE-:[921..921] *P*)))
      (CC:[922..925] and)
      (NP
        (NML (NN:[926..927] R) (CD:[928..930] 76) (CD:[931..934] 713))
        (NML-2 (NN:[935..944] treatment)))
      (PRN (-LRB-:[945..946] -LRB-)
        (FRAG
          (NP
            (NP
              (NP (CD:[946..947] 1)
                (NML-1 (-NONE-:[947..947] *P*)))
              (CC:[948..951] and)
              (NP (CD:[952..953] 5)
                (NML-1 (NN:[954..956] mg))))
            (PP (SYM:[956..957] /)
              (NP (NN:[957..959] kg))))
          (ADVP-TMP (RB:[960..965] twice)
            (NP (IN:[966..967] a) (NN:[968..971] day))))
        (-RRB-:[971..972] -RRB-)))
    (VP (VBD:[974..981] induced)
      (NP
        (NP
          (ADJP (RB:[982..988] almost) (JJ:[989..997] complete))
          (NN:[998..1008] regression))
        (PP (IN:[1009..1011] of)
          (NP
            (ADJP (NN:[1012..1044] 9,12-dimethyl-1,2-benzanthracene)
                  (HYPH:[1044..1045] -) (VBN:[1045..1052] induced))
            (JJ:[1054..1061] mammary) (NN:[1062..1071] carcinoma))))
      (PP-LOC (IN:[1072..1074] in)
        (NP (NNS:[1075..1079] rats))))
    (.:[1079..1080] .)))

;sentence 8 Span:1081..1246
;The appearance of new tumors during the treatment  period was completely
;inhibited by R 76 713 whilst multiplicity of the remaining  tumors was
;dramatically reduced.
;[1167..1175]:substance:"R 76 713"
(SENT
  (S
    (NP-SBJ-3
      (NP (DT:[1081..1084] The) (NN:[1085..1095] appearance))
      (PP (IN:[1096..1098] of)
        (NP (JJ:[1099..1102] new) (NNS:[1103..1109] tumors)))
      (PP-TMP (IN:[1110..1116] during)
        (NP (DT:[1117..1120] the) (NN:[1121..1130] treatment)
            (NN:[1132..1138] period))))
    (VP (VBD:[1139..1142] was)
      (ADVP (RB:[1143..1153] completely))
      (VP (VBN:[1154..1163] inhibited)
        (NP-3 (-NONE-:[1163..1163] *))
        (PP (IN:[1164..1166] by)
          (NP-LGS (NN:[1167..1168] R) (CD:[1169..1171] 76) (CD:[1172..1175] 713)))
        (SBAR-ADV
          (WHADVP-2 (IN:[1176..1182] whilst))
          (S
            (NP-SBJ-1
              (NP (NN:[1183..1195] multiplicity))
              (PP (IN:[1196..1198] of)
                (NP (DT:[1199..1202] the) (VBG:[1203..1212] remaining)
                    (NN:[1214..1220] tumors))))
            (VP (VBD:[1221..1224] was)
              (ADVP (RB:[1225..1237] dramatically))
              (VP (VBN:[1238..1245] reduced)
                (NP-1 (-NONE-:[1245..1245] *))
                (ADVP-TMP-2 (-NONE-:[1245..1245] *T*))))))))
    (.:[1245..1246] .)))

;section 9 Span:1250..1293
;PMID: 2098522 [PubMed - indexed for MEDLINE
(SEC
  (FRAG (NNP:[1250..1254] PMID) (::[1254..1255] :) (CD:[1256..1263] 2098522)
        (-LRB-:[1264..1265] -LSB-) (NNP:[1265..1271] PubMed) (::[1272..1273] -)
        (VBN:[1274..1281] indexed) (IN:[1282..1285] for)
        (NNP:[1286..1293] MEDLINE)))
;ERROR_Orphan Text from EOF Tree File[1293..EOF] ]

(ORPH -RSB-)
